Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06435910 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06435910 · ClinicalTrials.gov record · last posted 2026-08-27

Engineered Dendritic Cell Vaccines for Multiple Myeloma

StatusNot Yet Recruiting
PhasePhase 1
Started2027-06-30
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.

Protocol amendment history 3 changes detected by DataLookout

2026-08-28
Trial status changed: Recruiting → Not Yet Recruiting
2026-08-28
Primary completion pushed: 2027-07-11 → 2028-12-31
2026-08-28
Completion pushed: 2027-12-31 → 2029-12-31
Trial Details
NCT Number NCT06435910
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions Multiple Myeloma or Plasmacytoma
Enrollment 10 participants
Start Date 2027-06-30
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-27